Vlado Perkovic's Publications

• The effects of canagliflozin on uric acid and gout in patients with type 2 diabetes in the CANVAS programme

  Conference Abstracts

  2019

  DIABETOLOGIA

• Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply

  Journal articles

  2019

  The New England journal of medicine

• GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials

  Journal articles

  2019

  Journal of the American Society of Nephrology

• First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease

  Conference Papers

  2019

  EUROPEAN HEART JOURNAL

• Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial

  Journal articles

  2019

  Circulation

• Benefits and harms of oral anticoagulant therapy in chronic kidney disease

  Journal articles

  2019

  Annals of Internal Medicine

• SGLT2 inhibitor lowers risk of kidney failure in type 2diabetes

  Journal articles

  2019

  Pharmaceutical Journal

• Blood pressure: At what level is treatment worthwhile?

  Journal articles

  2019

  Australian Prescriber

• Is it time to REWIND the cardiorenal clock in diabetes?

  Journal articles

  2019

  The Lancet

• Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study

  Journal articles

  2019

  BMC Nephrology

• Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial

  Journal articles

  2019

  Journal of Renal Nutrition

• EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER

  Conference Abstracts

  2019

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS

  Conference Abstracts

  2019

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER

  Conference Abstracts

  2019

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• DIFFERENT EGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM

  Conference Abstracts

  2019

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

  Journal articles

  2019

  New England Journal of Medicine

• Combination of changes in estimated GFR and albuminuria and the risk of major clinical outcomes

  Journal articles

  2019

  Clinical Journal of the American Society of Nephrology

• Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial

  Journal articles

  2019

  DIABETES

• Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease

  Journal articles

  2019

  DIABETES

• SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS

  Journal articles

  2019

  Nephrology Dialysis Transplantation

• FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER

  Journal articles

  2019

  Nephrology Dialysis Transplantation

• FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER

  Journal articles

  2019

  Nephrology Dialysis Transplantation

• Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program

  Journal articles

  2019

  Diabetes

• FP484DIFFERENT eGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM

  Journal articles

  2019

  Nephrology Dialysis Transplantation

• 1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program

  Journal articles

  2019

  Diabetes

• Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptinwith renin-angiotensin system inhibitors in type 2 diabetic patientswith albuminuria

  Journal articles

  2019

  Journal of Hypertension